Xylazine and tiletamine-zolazepam anesthesia in horses.
The cardiopulmonary and anesthetic effects of xylazine in combination with a 1:1 mixture of tiletamine and zolazepam were determined in 6 horses. Each horse was given xylazine IV or IM, as well as tiletamine-zolazepam IV on 4 randomized occasions. Anesthetics were administered at the rate of 1.1 mg of xylazine/kg of body weight, IV, 1.1 mg of tiletamine-zolazepam/kg, IV (treatment 1); 1.1 mg of xylazine/kg, IV, 1.65 mg of tiletamine-zolazepam/kg, IV (treatment 2); 1.1 mg of xylazine/kg, IV, 2.2 mg of tiletamine-zolazepam/kg, IV (treatment 3); and 2.2 mg of xylazine/kg, IM, 1.65 mg of tiletamine-zolazepam/kg, IV (treatment 4). Tiletamine-zolazepam doses were the sum of tiletamine plus zolazepam. Xylazine, when given IV, was given 5 minutes before tiletamine-zolazepam. Xylazine, when given IM, was given 10 minutes before tiletamine-zolazepam. Tiletamine-zolazepam induced recumbency in all horses. Duration of recumbency in group 1 was 31.9 +/- 7.2 (mean +/- 1 SD) minutes. Increasing the dosage of tiletamine-zolazepam (treatments 2 and 3) significantly (P less than 0.05) increased the duration of recumbency. Xylazine caused significant (P less than 0.05) decreases in heart rate and cardiac output and significant (P less than 0.05) increases in central venous pressure and mean pulmonary artery pressure 5 minutes after administration. Respiratory rate was decreased. Arterial blood pressures increased significantly (P less than 0.05) after xylazine was administered IV in treatments 1 and 3, but the increases were not significant in treatment 2. Xylazine administered IM caused significant (P less than 0.05) increases in central venous pressure and significant (P less than 0.05) decreases in cardiac output.(ABSTRACT TRUNCATED AT 250 WORDS)
Hubbell
J A
JA
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Ohio State University, Columbus 43210.
Bednarski
R M
RM
Muir
W W
WW
D000771:Anesthesia, Intravenous / Q000662:veterinary*; D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D001784:Blood Gas Analysis / Q000662:veterinary; D001794:Blood Pressure / Q000187:drug effects; D003510:Cyclohexanes / Q000494:pharmacology*; D004338:Drug Combinations; D006339:Heart Rate / Q000187:drug effects; D006736:Horses / Q000502:physiology*; D012119:Respiration / Q000187:drug effects; D013843:Thiazines / Q000494:pharmacology*; D013992:Tiletamine / Q000494:pharmacology*; D013997:Time Factors; D014991:Xylazine / Q000494:pharmacology*; D015041:Zolazepam / Q000494:pharmacology*
D001381:Azepines; D003510:Cyclohexanes; D004338:Drug Combinations; D013843:Thiazines; D014991:Xylazine; D013992:Tiletamine; D015041:Zolazepam